Organization

Peking University Third Hospital

36 clinical trials

3 abstracts

Clinical trial
The Effect of Topical 0.05% Cyclosporine Eye Drops on Post-refractive Surgery Dry Eye
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
China Gender-affirming Hormone Therapy Study in Transgender Men and Women
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Effect of Metformin Intervention on Patients With Polycystic Ovary Syndrome
Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
A Randomized Controlled Clinical Trial of Effectiveness of Yunnan Baiyao in Improving Fracture Pain
Status: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
Clinical Evaluation of Enteral-extended Anti-reflux Stents for Pancreatic Pseudocyst
Status: Recruiting, Estimated PCD: 2025-07-31
Abstract
Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, The First Affiliated Hospital of Zhengzhou University,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.
Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.
Org: Peking University Third Hospital, Yanan City Hospital of Traditional Chinese Medicine,